Newsroom

25/08/2010
Company Statement - Shelf Life Reduction of Panvax^® Junior
Ongoing monitoring by both CSL and the TGA of CSL’s Panvax^® Junior vaccine has shown a decline in its potency and as a result a 12 month shelf life can no longer be supported. Panvax^® Junior is the paediatric presentation of CSL’s 2009 H1N1 (pandemic) influenza vaccine, which is supplied in a single 0.25ml pre-filled syringe. More.

30/07/2010
Update on Seasonal Influenza Vaccination of Children
CSL Limited (CSL) supports the statement made today by the Commonwealth Chief Medical Officer regarding seasonal flu vaccine for young children. More.

15/07/2010
CSL Announces New Biotech Facility
CSL Limited today announced a major biotechnology project at CSL’s manufacturing site in Broadmeadows, Australia. The centrepiece of the project will be the creation of Victoria’s first large scale biotechnology facility for the late stage development of new therapies for cancer, bleeding disorders, inflammation and infection. More.

29/06/2010
Media Statement - CSL receive "Untitled Letter" from FDA
On 24 June 2010, CSL received an “Untitled Letter” from the United States Food and Drug Administration (FDA) relating to a routine inspection it conducted at our Parkville manufacturing facility in April 2010. The inspection related to CSL’s seasonal and pandemic influenza vaccines licensed for use in the United States. More.

01/06/2010
Update on Seasonal Influenza Vaccination of Young Children
CSL Biotherapies (CSL) today notes the Chief Medical Officer’s statement and updated recommendations regarding influenza vaccination for children under 5. More.

23/04/2010
Seasonal influenza vaccine – paediatric adverse events
CSL Biotherapies is aware of reports of a number of adverse events following influenza vaccination of children. CSL is one of several suppliers of influenza vaccine in Australia. More.

16/04/2010
CSL subsidiary Marks World Hemophilia Day with Factor IX Donation to World Federation of Hemophilia
Hemophilia B patients in the developing world will benefit from a recent donation of 1 million international units (IU) of factor IX medication made by CSL Behring to the World Federation of Hemophilia (WFH). More.

30/03/2010
CSL Limited publishes first Corporate Responsibility Report
CSL Limited (ASX:CSL), Australia’s leading biopharmaceutical company, has released its first Corporate Responsibility Report, combining information about the Company’s economic, social and environmental performance for 2009. More.

21/12/2009
Findings of Australian trial of CSL’s Pandemic (H1N1) 2009
CSL Limited, Australia’s leading biopharmaceutical company, announced the Journal of the American Medical Association (JAMA) has published data from a clinical trial conducted in Australia to study CSL’s pandemic H1N1 2009 ‘swine' flu vaccine. More.

10/12/2009
Vaccine to treat gum disease on the way
CSL Limited, Australia’s leading biopharmaceutical company, has today announced that a vaccine to treat severe gum disease is being developed in a new collaboration with Sanofi Pasteur, the world’s leading global manufacturer of vaccines. More.

08/12/2009
CHANGES TO CSL SENIOR EXECUTIVE GROUP
CSL Limited (ASX:CSL), Australia’s leading biopharmaceutical company, announced today a number of changes in its organisation structure and its senior executive group, within the context that Dr Brian McNamee would be continuing as CEO and Managing Director for at least a further three to four years. More.

>> Prior Archived Newsroom

Media Enquiries - CSL Limited
Sharon McHale
Senior Director Public Affairs
Phone: +613 9389 1506
Mobile: +61 409 978 314
Email: sharon.mchale@csl.com.au
45 Poplar Rd, Parkville
Victoria 3052
Australia

Media Enquiries - CSL Behring
Kelly Fox
Phone: +1 610 878 4369
Fax: +1 610 878 4584
Email: kelly.fox@cslbehring.com
1020 First Avenue
PO Box 61501
King of Prussia, PA 19406-0901
USA

Privacy | Terms of Use | Employees | Webmaster